Dr. Sara Lynne Kennedy, M.D. M.P.H. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2185 Pacheco St, Concord, CA 94520 Phone: 925-676-0505 Fax: 925-676-2814 |
Emily C. Corrigan, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2000 Sierra Road, Concord, CA 94518 Phone: 408-554-9820 |
Jeffrey Mark Waldman, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2185 Pacheco St, Concord, CA 94520 Phone: 925-676-0505 |
Dr. Leslie Katherine Drummond-hay, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2185 Pacheco St, Concord, CA 94520 Phone: 925-676-0505 Fax: 925-676-2814 |
Anita Kotamraju Rama, M.D Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2425 East Street #14, Concord, CA 94520 Phone: 925-676-7622 |
Mehrnoosh Almassi, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2700 Grant St, Suite 306, Concord, CA 94520 Phone: 925-356-8990 Fax: 925-356-8997 |
News Archive
"The United States and Sudan traded accusations [on Tuesday] over the humanitarian situation in the [border] states of Blue Nile and South Kordofan, embattled since the north and south of Sudan split into two nations last summer," the New York Times reports (MacFarquhar, 1/17).
A study published in the journal Cell shows that the gut microbiota has the ability to affect how cells respond to insulin, and can thus contribute to type 2 diabetes. The findings demonstrate an hereto unknown pathological mechanism.
A review of previously published articles indicates there is little evidence supporting an effective treatment of bites from bed bugs, that these insects do not appear to transmit disease, and control and eradication of bed bugs is challenging, according to an article in the April 1 issue of JAMA .
Initiate Systems, Inc., a leader in data management solutions for information sharing and improved data quality, has acquired Accenx Technologies, Inc., a leading provider of health information exchange solutions. This acquisition furthers Initiate's growth strategy and expands its offerings in the healthcare market. The terms of the deal are confidential.
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.
› Verified 3 days ago